Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
2027. jún. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
2027. jan. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
2027. jan. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC
2027. jan. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
2026. dec. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2
2026. nov. 30.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
2026. nov. 30.· PHASE2 · RECRUITING· CTGOV
Vizsgálat
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
2026. nov. 30.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer
2026. nov. 10.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.
2026. nov. 6.· The oncologist· PUBMED
Publikáció
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations.
2026. nov. 6.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway.
2026. nov. 5.· Oncogene· PUBMED
Publikáció
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations.
2026. nov. 3.· Molecular cancer therapeutics· PUBMED
Publikáció
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
β-elemene suppressed EMT via IGF1R inhibition in osimertinib treated AXL low-expressing EGFR mutant non-small cell lung cancer.
2026. nov. 2.· European journal of pharmacology· PUBMED
Publikáció
PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma.
2026. nov. 2.· Molecular pharmaceutics· PUBMED
Vizsgálat
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Predicting early EGFR-TKI treatment response in EGFR-mutant lung adenocarcinoma from H&E histopathology with weakly supervised multiple-instance learning.
2026. nov. 1.· Pathology, research and practice· PUBMED
Publikáció
Protocol of a Real-World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (SPIRAL-RACER20 Study).
2026. nov. 1.· Thoracic cancer· PUBMED
Publikáció
Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer.
2026. nov. 1.· The journal of pathology. Clinical research· PUBMED
Publikáció
Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report.
2026. nov. 1.· Thoracic cancer· PUBMED
Publikáció
Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer.
2026. nov. 1.· Protein & cell· PUBMED
Publikáció
Machine learning-assisted Ti3C2Tx MXene/Au@Fe3O4 core-shell nanocomposite-based electrochemical genosensor for ultrasensitive detection of EGFR T790M mutation in lung cancer.
2026. okt. 31.· Mikrochimica acta· PUBMED
Vizsgálat
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
2026. okt. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer
2026. okt. 30.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Brief report: Clinical and Functional Characterization of Rare Germline and Somatic EGFR Variants in Three Patients with Non-Small Cell Lung Cancer.
2026. okt. 30.· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED